# Sentinel Oncology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sentinel-oncology

- Industry: Healthcare
- Headquarters: Cambridge, UK
- Website: www.sentineloncology.com
- Total disclosed funding: $0.2M
- Latest round: Seed (Aug 5, 2006)
- Investors on record: 1

## About

Sentinel Oncology focuses on the development of targeted oncology therapeutics, aiming to address critical medical needs in cancer treatment through its innovative drug candidates.Sentinel Oncology, founded in 2005, is headquartered in Cambridge, UK, and specializes in developing therapies for primary brain tumors and systemic tumors. The company has completed 5 deals, with its most recent deal on April 12, 2010, involving a Grant of GBP 1.300 mn from Wellcome Trust. The founder, Gavin Simpson, has a background in oncology, contributing to the vision of advancing cancer treatment through targeted therapies.Sentinel Oncology specializes in the development and commercialization of innovative oncology therapeutics, focusing on highly selective and targeted candidate drugs for treating primary brain tumors and systemic tumors that metastasize to the brain. The company's pipeline includes drug candidates poised for phase 1 clinical trials, addressing a significant patient population with various brain cancer types in the US and Europe.Sentinel Oncology derives its revenue from strategic partnerships, licensing agreements, and clinical development milestones. The firm collaborates with pharmaceutical companies and research institutions, positioning itself in a B2B framework. Revenue generation will begin upon market approval of its drug candidates, including SOL578, which are anticipated to proceed toward commercialization in line with ongoing clinical trials.Sentinel Oncology intends to leverage its recent Grant financing of GBP 1.300 mn to support the advancement of its clinical drug candidates and expand its market reach into new geographic regions, particularly further into the European market by 2025. The company aims to launch its innovative therapies, enhancing its pipeline with the upcoming phase 1 clinical trials.

## Funding rounds

- Seed, Aug 5, 2006, $0.2M — Cambridge Enterprise

## Investors

- Cambridge Enterprise — Seed